Tg Therapeutics, Inc. financial data

Symbol
TGTX on Nasdaq
Location
2 Gansevoort Street, 9 Th Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 447 % +3.06%
Quick Ratio 92.7 % +27.6%
Debt-to-equity 172 % +47.5%
Return On Equity -354 %
Return On Assets 9.59 % -64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 159M shares +2.48%
Common Stock, Shares, Outstanding 158M shares +2.06%
Entity Public Float 2.5B USD -26.5%
Common Stock, Value, Issued 159K USD +2.58%
Weighted Average Number of Shares Outstanding, Basic 147M shares +1.39%
Weighted Average Number of Shares Outstanding, Diluted 163M shares +1.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 454M USD +31%
Research and Development Expense 122M USD +48.1%
Costs and Expenses 368M USD +50.4%
Operating Income (Loss) 85.8M USD -15.7%
Nonoperating Income (Expense) -19.7M USD -225%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 66.1M USD -31%
Income Tax Expense (Benefit) 5.65M USD
Net Income (Loss) Attributable to Parent 60.5M USD -36.8%
Earnings Per Share, Basic 0 USD/shares -42%
Earnings Per Share, Diluted 0 USD/shares -44.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 129M USD +55.7%
Cash, Cash Equivalents, and Short-term Investments 279M USD +28.3%
Accounts Receivable, after Allowance for Credit Loss, Current 232M USD +177%
Inventory, Net 155M USD +91%
Other Assets, Current 25.4M USD +260%
Assets, Current 664M USD +70.6%
Property, Plant and Equipment, Net 66K USD -72.2%
Operating Lease, Right-of-Use Asset 6.72M USD -12.3%
Goodwill 799K USD 0%
Other Assets, Noncurrent 2.03M USD -5.94%
Assets 703M USD +75.1%
Liabilities, Current 172M USD +58.2%
Operating Lease, Liability, Noncurrent 7.59M USD -12.7%
Liabilities 426M USD +90.6%
Retained Earnings (Accumulated Deficit) -1.5B USD +3.88%
Stockholders' Equity Attributable to Parent 276M USD +55.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 40.5M USD -68.7%
Liabilities and Equity 703M USD +75.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.7M USD -250%
Net Cash Provided by (Used in) Financing Activities -6.1M USD -161%
Net Cash Provided by (Used in) Investing Activities -12.9M USD -39.8%
Common Stock, Shares Authorized 190M shares 0%
Common Stock, Shares, Issued 159M shares +2.53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -47.8M USD -174%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 130M USD +54.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6.14M USD +151%
Deferred Tax Assets, Valuation Allowance 415M USD -0.89%
Deferred Tax Assets, Gross 415M USD -0.89%
Operating Lease, Liability 8.68M USD -13.2%
Depreciation 68K USD -10.5%
Payments to Acquire Property, Plant, and Equipment 25K USD
Lessee, Operating Lease, Liability, to be Paid 11.6M USD -16.3%
Operating Lease, Liability, Current 1.09M USD -16.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.91M USD -8.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.08M USD -0.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.89M USD -24.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.83M USD -4.5%
Deferred Tax Assets, Operating Loss Carryforwards 294M USD -7.23%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.83M USD 0%
Operating Lease, Payments 500K USD -16.7%
Additional Paid in Capital 1.79B USD +3.47%
Amortization of Intangible Assets 53K USD 0%
Depreciation, Depletion and Amortization 8K USD -72.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 55.1M USD +47.3%
Interest Expense 12.1M USD +16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%